Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation
Completed
Mundipharma Research GmbH & Co KG
Phase 3
2006-04-01
The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged
release tablets have improvement in symptoms of constipation compared to subjects taking
oxycodone prolonged release tablets alone.
Oxycodone-naloxone in Relieving Opioid-related Constipation
Completed
Mundipharma Research GmbH & Co KG
Phase 3
2006-01-01
The primary objective of this study is to demonstrate that subjects with moderate to severe
non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in
symptoms of constipation compared to subjects taking oxycodone prolonged release tablets
alone.
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
Completed
Mundipharma Research GmbH & Co KG
Phase 2
2007-09-01
The purpose of this study is to test the oxycodone/naloxone combination compared to oxycodone
alone in patient's specific type of "chronic cancer pain".
A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis
Completed
Napp Pharmaceuticals Limited
Phase 4
2009-02-01
The purpose of this study is to compare oxycodone/naloxone combination tablet and
codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or
pain due to osteoarthritis.
OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
Completed
Mundipharma Research GmbH & Co KG
Phase 3
2009-05-01
The primary objectives are
- to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment
with OxyPR with regards to analgesic efficacy and locomotor function.
- to demonstrate that subjects with moderate to severe OA pain taking oxycodone/naloxone
prolonged release tablets have improvement in symptoms of constipation compared to
subjects taking oxycodone prolonged release tablets alone
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
